ATE94387T1 - Verwendung von n-myristoyl-(s)-phenylalanin zur herstellung eines medikaments zur behandlung von krankheiten mittels hemmung der myristoylierung. - Google Patents

Verwendung von n-myristoyl-(s)-phenylalanin zur herstellung eines medikaments zur behandlung von krankheiten mittels hemmung der myristoylierung.

Info

Publication number
ATE94387T1
ATE94387T1 AT91400163T AT91400163T ATE94387T1 AT E94387 T1 ATE94387 T1 AT E94387T1 AT 91400163 T AT91400163 T AT 91400163T AT 91400163 T AT91400163 T AT 91400163T AT E94387 T1 ATE94387 T1 AT E94387T1
Authority
AT
Austria
Prior art keywords
myristoyl
phenylalanine
diseases
treatment
myristoylation
Prior art date
Application number
AT91400163T
Other languages
English (en)
Inventor
Michel Vincent
Georges Remond
Yolande Herve
Jean-Albert Boutin
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Application granted granted Critical
Publication of ATE94387T1 publication Critical patent/ATE94387T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT91400163T 1990-01-25 1991-01-25 Verwendung von n-myristoyl-(s)-phenylalanin zur herstellung eines medikaments zur behandlung von krankheiten mittels hemmung der myristoylierung. ATE94387T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9000834A FR2657259A1 (fr) 1990-01-25 1990-01-25 Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.

Publications (1)

Publication Number Publication Date
ATE94387T1 true ATE94387T1 (de) 1993-10-15

Family

ID=9393082

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91400163T ATE94387T1 (de) 1990-01-25 1991-01-25 Verwendung von n-myristoyl-(s)-phenylalanin zur herstellung eines medikaments zur behandlung von krankheiten mittels hemmung der myristoylierung.

Country Status (14)

Country Link
US (1) US5164414A (de)
EP (1) EP0443891B1 (de)
JP (1) JPH0717503B2 (de)
AT (1) ATE94387T1 (de)
AU (1) AU633395B2 (de)
CA (1) CA2034861A1 (de)
DE (1) DE69100364T2 (de)
DK (1) DK0443891T3 (de)
ES (1) ES2060310T3 (de)
FR (1) FR2657259A1 (de)
IE (1) IE65573B1 (de)
OA (1) OA09478A (de)
PT (1) PT96571A (de)
ZA (1) ZA91574B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672598A1 (fr) * 1991-02-11 1992-08-14 Adir Nouveaux inhibiteurs de n-myristoyltransferase, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5599947A (en) * 1993-01-14 1997-02-04 G. D. Searle & Co. Fatty acid analogs and prodrugs
US6127393A (en) 1995-12-29 2000-10-03 Novactyl, Inc. Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
US6407125B1 (en) 1995-12-29 2002-06-18 Novactyl, Inc. Pharmacological agent and method of treatment
US6743771B2 (en) 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US6579891B1 (en) 1995-12-29 2003-06-17 Novactyl, Inc. Agent and method for prevention and treatment of cancer in animals
US6441009B1 (en) 1998-08-01 2002-08-27 Novactyl, Inc. Agent and method of preventing and treating heavy metal exposure and toxicity
CA2704975A1 (en) * 1999-10-13 2001-05-31 Marco A. Chacon Therapeutic intervention to mimic the effect of caloric restriction
US6403618B1 (en) 2000-02-15 2002-06-11 Novactyl, Inc. Agent and method for controlling angiogenesis
US20030022938A1 (en) * 2001-06-25 2003-01-30 Burstein Sumner H. N-fatty acid-amino acid conjugates and therapeutic uses
DE10353806A1 (de) * 2003-11-14 2005-07-07 Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Gesundheit, dieses vertreten durch das Robert-Koch-Institut, vertreten durch seinen Präsidenten Verwendung von Aminosäure- und Zucker-Amphiphilen zur Inaktivierung von lipidumhüllten Viren
US7544714B2 (en) * 2004-07-16 2009-06-09 University Of Massachusetts Lipid-amino acid conjugates and methods of use
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
BR112014001430A2 (pt) * 2011-07-22 2017-02-21 Pacylex Pharmaceuticals Inc letalidade sintética e o tratamento do câncer
EP2830441B1 (de) 2012-03-30 2019-11-13 Givaudan SA N-acylderivate aus gamma-amino-buttersäure als nahrungsmittelgeschmackstoffe
BR122020006518B1 (pt) 2012-03-30 2022-02-22 Givaudan Sa Composição de sabor
CN104302191A (zh) 2012-03-30 2015-01-21 奇华顿股份有限公司 用于改善可食用组合物香味特性的n-酰基-氨基酸衍生物
JP6209588B2 (ja) 2012-03-30 2017-10-04 ジボダン エス エー 食品フレーバー付与化合物としてのｎ−アシルプロリン誘導体
SG11201405409PA (en) 2012-03-30 2014-11-27 Givaudan Sa N-acylated 1 - aminocycloalkyl carboxylic acids as food flavouring compounds
US10913922B2 (en) 2012-03-30 2021-02-09 Givaudan S.A. N-acylated methionine derivatives as food flavoring compounds
CN104219963B (zh) 2012-03-30 2018-08-14 奇华顿股份有限公司 作为食品加香化合物的n-酰基-氨基酸衍生物、包含它们的粉末组合物
DK2914261T3 (da) * 2012-10-30 2021-03-22 Pacylex Pharmaceuticals Inc Syntetisk letalitet og behandling af cancer
EP3057448B1 (de) 2013-10-02 2017-12-06 Givaudan S.A. Organische verbindungen mit geschmacksmodifizierenden eigenschaften
WO2015048991A1 (en) 2013-10-02 2015-04-09 Givaudan Sa Organic compounds having taste-modifying properties
GB201317424D0 (en) 2013-10-02 2013-11-13 Givaudan Sa Improvements in or relating to organic compounds
WO2015050536A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. N-acylated 2-aminoisobutyric acid compounds and flavour compositions containing them
CN105658089B (zh) 2013-10-02 2019-07-09 奇华顿股份有限公司 有机化合物
US10834950B2 (en) 2013-10-02 2020-11-17 Givaudan S.A. Organic compounds
WO2015050535A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
US10834943B2 (en) 2013-10-02 2020-11-17 Givaudan S.A. Organic compounds having taste-modifying properties
WO2017011907A1 (en) 2015-07-17 2017-01-26 Pacylex Pharmaceuticals Inc. Epigenetic silencing of nmt2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778877A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides II
US4778878A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides I

Also Published As

Publication number Publication date
CA2034861A1 (fr) 1991-07-26
AU633395B2 (en) 1993-01-28
IE65573B1 (en) 1995-11-01
DK0443891T3 (da) 1993-12-27
JPH04210916A (ja) 1992-08-03
DE69100364T2 (de) 1994-04-21
IE910242A1 (en) 1991-07-31
EP0443891A1 (de) 1991-08-28
JPH0717503B2 (ja) 1995-03-01
ZA91574B (en) 1991-11-27
US5164414A (en) 1992-11-17
PT96571A (pt) 1991-10-15
FR2657259A1 (fr) 1991-07-26
AU6998791A (en) 1991-08-01
EP0443891B1 (de) 1993-09-15
FR2657259B1 (de) 1994-08-19
OA09478A (fr) 1992-11-15
DE69100364D1 (de) 1993-10-21
ES2060310T3 (es) 1994-11-16

Similar Documents

Publication Publication Date Title
ATE94387T1 (de) Verwendung von n-myristoyl-(s)-phenylalanin zur herstellung eines medikaments zur behandlung von krankheiten mittels hemmung der myristoylierung.
DE10199020I1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
DE69109560D1 (de) Fungizide Zusammensetzung zur Behandlung von Saatgut.
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DE122005000002I1 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
DE69229944D1 (de) Verwendung von N-Acylaminoalkoholen zur Herstellung eines Arzneimittels zur Behandlung von Mastzellerkrankungen
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
ATE137116T1 (de) Behandlung von entzündlichen erkrankungen mit 15- ketoprostaglandinen
DE69130679D1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
ATE83378T1 (de) Verwendung von 3'-azido-deoxythymidin zur herstellung eines arzneimittels zur behandlung von humanen brustcarzinomen.
FI951511A (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
DE69110779D1 (de) Schilddrüsenhormone zur kardialen behandlung.
ATE209914T1 (de) Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
DE69313261D1 (de) Verwendung von LACTOFERRIN zur Herstellung eines THERAPEUTISCHEN MITTELS zur Behandlung von RHEUMATISMUS
DE69232911D1 (de) Verwendung eines polyhydroxybenzamids oder dessen Derivat zur Herstellung eines Medikaments für die Behandlung von viralen Infektionen
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
DE69026511D1 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
NO913117L (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
DE3686097D1 (de) Verwendung von dopamin-agonisten zur herstellung eines arzneimittels zur behandlung von psychostimulant-sucht.
DE3873188D1 (de) Verwendung von nigerizin zur herstellung eines mittels zur behandlung von virus-erkrankungen.
DE69124415D1 (de) Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE69424415D1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
DE69228235D1 (de) Verwendung eines Mittels zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankung